Medical and economic interest of the use of cryosurgery in the instrumental treatment of atrial fibrillation

Pharmacology. 2011;87(1-2):28-35. doi: 10.1159/000322524. Epub 2010 Dec 20.

Abstract

Introduction: In order to definitively integrate cryosurgery for the surgical treatment of atrial fibrillation (AF) into the therapeutic armamentarium, the medical and economic impact of its use on a population of patients with a high risk of recurrence of postoperative AF must be evaluated.

Method: An observational study of patients who benefited from cryosurgery between July 2006 and December 2008 was performed. The cost of consumables and hospitalization was determined and compared to that of a control group of 27 patients with preoperative AF that had not benefited from cryosurgery.

Results: Twenty-nine patients benefited from cryosurgery during a mitral (65.5%) or aortic intervention (37.9%) to treat a paroxystic (44.8%) or permanent AF (55.2%). More than half of them (58.6%) had a 12-month follow-up; 82.4% of these patients showed a permanent sinus rhythm and 32.6% had stopped their antiarrhythmic medication. There was no significant difference between the duration and cost of hospitalization for the 2 groups.

Conclusion: Cryosurgery provides a clear clinical and economic advantage with no recurrence of AF, and it reduces antiarrhythmic medication treatment.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Arrhythmia Agents / therapeutic use
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / economics*
  • Atrial Fibrillation / surgery*
  • Cardiac Surgical Procedures
  • Cryosurgery / adverse effects*
  • Cryosurgery / economics*
  • Female
  • France
  • Health Care Costs*
  • Heart Diseases / complications
  • Heart Diseases / surgery
  • Hospitals, University
  • Humans
  • Length of Stay
  • Male
  • Medical Records
  • Middle Aged
  • Retrospective Studies
  • Secondary Prevention
  • Technology Assessment, Biomedical
  • Treatment Outcome

Substances

  • Anti-Arrhythmia Agents